We hold LightPath Technologies (LPTH) starting at $1.40-$1.60 in January 2017 and suggest long-term ...
Cellular Biomedicine: Delivering on All Fronts
06/30/2015 7:00 am EST
One of our recommended biotech companies has just acquired the rights to an off-the-shelf cancer vaccine, a next generation GVAX, observes biotech expert John McCamant, editor of The Medical Technology Stock Letter.
The inventor of CD40-GVAX, Scott Antonia, MD, PhD is currently the department chair of thoracic oncology and program leader of the immune-oncology program at the Moffitt Cancer Center.
Dr. Antonia ranks among the foremost experts in the world of immuno-oncology and is an active collaborator with large pharmaceutical companies.
He is recognized as one of the world's leading authorities in the treatment of lung cancer with immune-therapeutics and has recently joined the CBMG Scientific Advisory Board.
Given the positive Phase I results of CD40-GVAX alone in non-small cell lung cancer, Dr. Antonia plans to combine the drug with a checkpoint inhibitor, nivolumab, in a three patient lead-in Phase I clinical trial.
This will be followed by a randomized Phase II clinical trial in the US to evaluate the safety and efficacy of the combination in patients with Stage IV non-small cell lung cancer.
The clinical trails are expected to begin in the second half of 2015. This is a huge market opportunity in China, with 728,552 people diagnosed with lung cancer in 2012.
Meanwhile, the company is running a Phase IIb trails for Rejoin, testing their stem cell therapy in patients with knee osteoarthritis.
Its pre-clinical stem cell data was published in the May edition of the International Journal of Molecular Science.
Data that is published in peer-reviewed journals is one of the primary methods to both validate technology and demonstrate that value has been created.
Cellular Biomedicine continues to deliver on all fronts as they assemble a world-class pipeline that, we believe, is still below Wall Street's radar.
The additional of Dr. Antonia to CBMG's scientific advisory board is a coup for the company and provides further validation for its pipeline.
Overall, the company provides a diversified investment opportunity with an excellent pipeline and a stem cell product line for less than $500 million. The stock is a buy under $40 with a target price of $55.
More from MoneyShow.com:
Related Articles on STOCKS
The best corporate managers are always one step ahead. Salesforce is the second coming of Amazon.com...
Now about new highs being celebrated, amidst deterioration of a slew of internals: This suggests nei...
Our daily breakout stock ideas are most suitable for aggressive investors seeking ideal entry points...